The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report

M. C. Hardenberg, B. Patel, C. Matthews, R. Califano, R. Garcia Campelo, C. Grohe, M. H. Hong, G. Liu, S. Lu, F. de Marinis, M. Pérol, R. A. Soo, B. M. Stiles, M. Tiseo, M. Tsuboi

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report'. Together they form a unique fingerprint.

Medicine & Life Sciences